Brokerage firm slashes Orphazyme price target by 77 percent
Following the CHMP’s indication that biotech firm Orphazyme’s drug candidate for rare metabolic disease Niemann-Pick type C will soon be rejected, institutional brokerage firm Danske Markets has decided to further reduce the company share price target.
by marketwire, translated by daniel pedersen
Biotech company Orphazyme has had its share price target lowered to a mere DKK 3 (USD 0.45) from a previous DKK 13 (USD 1.95) by Danish brokerage firm Danske Markets. The firm maintains its recommendation ”sell,” according to financial news service PLX AI.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme stock plummets following bad news from CHMP
For subscribers
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
